High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus
Abstract
The pharmacological armamentarium for the treatment of SLE is expanding and a number of novel therapies are currently under investigation. In spite of this, steroid therapy remains the cornerstone of treatment and intravenous methylprednisolone (IVMP) is still widely used in clinical practice. There is however surprisingly little evidence on which to define its precise role. The objective of this review was to consider the published evidence relating to the use of IVMP in SLE patients and also to identify open questions that still need to be answered with regard to its use. In acute flares, IVMP induces rapid suppression of acute inflammation. There is not however a strong evidence base to support the use of high doses compared to low IVMP doses or oral prednisolone. In maintenance regimes, secondary analyses suggest that IVMP may confer additional long-term renal survival over oral steroids as part of a cyclophosphamide regime. Therefore, in addition to the evaluation of novel therapies for SLE, better evidence to define the precise role of IVMP in SLE is still required. ( Lupus (2007) 16, 387—393)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The efficacy of low-dose GCs (≤7.5 mg prednisolone equivalent daily) on disease activity in various conditions is well established.
“Although the efficacy of these doses on disease activity in various conditions is well established [1–4, 7]”
From Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial (2011) · cites this paper as [4]
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519 · see citing works
Mycophenolate mofetil and its mechanisms of action
ALLISON, A. C., & Eugui, E. M. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00188-0 · Cited by 1,433 · see citing works
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C. B., Kim, M., Buyon, J. P., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,122 · see citing works
Houssiau, F., Vasconcelos, C., D’Cruz, D. P., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramowicz, D., Blockmans, D., Mathieu, A., Di̇reskeneli̇, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,074 · see citing works
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F., Tang, C. S.-O., Wong, R. W. S., Fang, G. X., Ji, Y., Lau, C. S., Wong, A. K., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 949 · see citing works
(2015) · European Journal Of Haematology · doi:10.1111/ejh.12636 · Cited by 780 · see citing works
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F. M., Arend, L. J., Sloand, J. A., Rosenblatt, J. D., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 779 · see citing works
Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis
Gourley, M. F., Austin, H. A., III, Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 604 · see citing works
Buttgereit, F., Da Silva, J. A. P., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., Kirwan, J., Köhler, L., van Riel, P., Vischer, T., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.718 · Cited by 544 · see citing works
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 487 · see citing works
Barile-Fabris, L. A., Ariza-Andraca, R., Olguín-Ortega, L., Jara, L. J., Fraga-Mouret, A., Miranda-Limón, J. M., de la Mata, J. F., Clark, P., Vargas, F., & Alocer-Varela, J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.025528 · Cited by 338 · see citing works
Kovacs, B., Lafferty, T. E., Brent, L. H., & DeHoratius, R. J. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.2.120 · Cited by 332 · see citing works
Infectious complications in SLE after immunosuppressive therapies
Kang, I., & Park, S. H. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200309000-00002 · Cited by 256 · see citing works
Mok, C. C. (2000) · British journal of rheumatology · doi:10.1093/rheumatology/39.4.399 · Cited by 203 · see citing works
Roubenoff, R., & Hochberg, M. C. (1991) · Springer eBooks · doi:10.1007/978-94-011-3896-3_9 · Cited by 149 · see citing works
Ibañez, D., Gladman, D. D., & Urowitz, M. B. (2005) · PubMed · Cited by 141 · see citing works
Epidemiology of systemic lupus erythematosus.
Manzi, S. (2001) · PubMed · Cited by 120 · see citing works
Intravenous pulses of methylprednisolone for systemic lupus erythematosus
Badsha, H., & Edwards, C. J. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2002.50003 · Cited by 110 · see citing works
Hochberg, M. C. (1990) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00891-7 · Cited by 98 · see citing works
Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus?
Albert, D., Hadler, N. M., & Ropes, M. W. (1979) · Arthritis & Rheumatism · doi:10.1002/art.1780220901 · Cited by 83 · see citing works
Badsha, H., Kong, K. O., Lian, T. Y., Chan, S. P., Edwards, C. J., & Chng, H. H. (2002) · Lupus · doi:10.1191/0961203302lu243oa · Cited by 78 · see citing works
Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus.
Isenberg, D. A., Morrow, W. J., & Snaith, M. L. (1982) · Annals of the Rheumatic Diseases · doi:10.1136/ard.41.4.347 · Cited by 76 · see citing works
Quattrocchi, E., Dallman, M. J., & Feldmann, M. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8 · Cited by 65 · see citing works
Methylprednisolone pulse therapy for nonrenal lupus erythematosus.
Eyanson, S., Passo, M. H., Aldo‐Benson, M. A., & Benson, M. D. (1980) · Annals of the Rheumatic Diseases · doi:10.1136/ard.39.4.377 · Cited by 65 · see citing works
Flanc, R. S., Roberts, M. A., Strippoli, G. F., Chadban, S. J., Kerr, P. G., & Atkins, R. C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002922.pub2 · Cited by 65 · see citing works
Ioannou, Y., & Isenberg, D. A. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.924.599 · Cited by 60 · see citing works
Acute and Long-term Complications of Corticosteroid Pulse Therapy
Wollheim, F. A., & Wollheim, F. A. (1984) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748409103858 · Cited by 59 · see citing works
The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases
Pyne, D. B. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.4.367 · Cited by 59 · see citing works
Vasoo, S., Thumboo, J., & Fong, K. (2002) · Lupus · doi:10.1191/0961203302lu224oa · Cited by 58 · see citing works
Monthly pulses of methylprednisolone in SLE nephritis.
Liebling, M. R., McLaughlin, K., Boonsue, S., Kasdin, J., & Barnett, E. V. (1982) · PubMed · Cited by 55 · see citing works
Edwards, J. C. W., Snaith, M. L., & Isenberg, D. A. (1987) · Annals of the Rheumatic Diseases · doi:10.1136/ard.46.10.773 · Cited by 47 · see citing works
Treatment of Diffuse Proliferative Lupus Nephritis by Intravenous High-dose Methylprednisolone
Ponticelli, C. E., Zucchelli, P. C., Banfi, G., Cagnoli, L., Scalia, P., Pasquali, S., & Imbasciati, E. (1982) · QJM · doi:10.1093/oxfordjournals.qjmed.a067704 · Cited by 45 · see citing works
Trevisani, V. F. M., Castro, A., Neto, J. N., & Atallah, A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002265 · Cited by 42 · see citing works
Pulse methylprednisolone therapy for persistent subacute cutaneous lupus
Goldberg, J. W., & Lidsky, M. D. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270720 · Cited by 39 · see citing works
Mackworth-Young, C. G., David, J., Morgan, S. H., & Hughes, G. R. V. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.6.496 · Cited by 36 · see citing works
Pharmacological Aspects of Corticosteroid Pulse Therapy
Pentikäinen, P. J., & Pentikäinen, P. J. (1984) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748409103852 · Cited by 29 · see citing works
Kong, K., Badsha, H., Lian, T. Y., Edwards, C. J., & Chng, H. H. (2004) · Lupus · doi:10.1191/0961203304lu510xx · Cited by 26 · see citing works
Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus.
Lurie, D. P., & Kahaleh, M. B. (1982) · PubMed · Cited by 25 · see citing works
Corticosteroids in rheumatic disease
van Vollenhoven, R. (1998) · Postgraduate Medicine · doi:10.3810/pgm.1998.02.349 · Cited by 22 · see citing works
Sp, B., Ma, K., & Kushner, I. (1985) · PubMed · Cited by 19 · see citing works
Bertoni, M., Brugnolo, F., Bertoni, E., Salvadori, M., Romagnani, S., & Emmi, L. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103033 · Cited by 9 · see citing works
The Effects of “Pulse” Corticosteroid Therapy on the Immune System
Kurki, P., & Kurki, P. (1984) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748409103854 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
Guiducci, C., Gong, M., Xu, Z., Gill, M. A., Chaussabel, D., Meeker, T., Chan, J. H., Wright, T. B., Punaro, M., Bolland, S. M., et al. (2010) · Nature · doi:10.1038/nature09102 · Cited by 380 · see citing works
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D. P., Empson, B., Griffiths, B., Jayne, D. R. W., Khamashta, M. A., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 363 · see citing works
Self-citationPragmatic approaches to therapy for systemic lupus erythematosus
Xiong, W., & Lahita, R. G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.157 · Cited by 113 · see citing works
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2174-9 · Cited by 109 · see citing works
“Although the efficacy of these doses on disease activity in various conditions is wellestablished [1-4;7], the extent to which these low dosages induce adverse metabolic effects is unclear.”
BackgroundGlucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Porta, S., Danza, Ã., Saavedra, M. A., Carlomagno, A., Goizueta, M. C., Vivero, F., & Ruiz‐Irastorza, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092709 · Cited by 101 · see citing works
Ruiz‐Arruza, I., Lozano, J., Cabezas‐Rodríguez, I., Medina, J., Ugarte, A., Erdozain, J. G., & Ruiz‐Irastorza, G. (2017) · Arthritis Care & Research · doi:10.1002/acr.23322 · Cited by 97 · see citing works
Glucocorticoids in systemic lupus erythematosus.
Mosca, M., Tani, C., Carli, L., & Bombardieri, S. (2011) · PubMed · Cited by 86 · see citing works
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions
Ugarte, A., Danza, Ã., & Ruiz‐Irastorza, G. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000527 · Cited by 79 · see citing works
Neurological Complications in Patients with Systemic Lupus Erythematosus
Shaban, A., & Leira, E. C. C. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1012-1 · Cited by 79 · see citing works
Kasturi, S. P. T., & Sammaritano, L. R. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.007 · Cited by 71 · see citing works
Systemic lupus erythematosus: pathogenesis and targeted therapy
Su, X., Yu, H. M., Lei, Q., Chen, X., Tong, Y., Zhang, Z., Yang, W., Guo, Y., & Lin, L. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00217-8 · Cited by 84 · see citing works
New directions in the treatment of systemic lupus erythematosus
KALUNIAN, K. C., & Joan, T. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902929104 · Cited by 69 · see citing works
Tomiyama, T., Uchida, K., Matsushita, M., Ikeura, T., Fukui, T., Takaoka, M., Nishio, A., & Okazaki, K. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0361-y · Cited by 66 · see citing works
Immunomodulatory Therapies in Neurologic Critical Care
McDaneld, L. M., Fields, J. D., BOURDETTE, D. N., & Bhardwaj, A. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9274-0 · Cited by 62 · see citing works
Little, J., Parker, B., Lunt, M., Hanly, J. G., Urowitz, M. B., Clarke, A. E., Romero‐Díaz, J., Gordon, C., Bae, S., Bernatsky, S., et al. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex444 · Cited by 55 · see citing works
Self-citationTatsuno, I., Sugiyama, T., Suzuki, S., Yoshida, T., Tanaka, T., Sueishi, M., & Saitō, Y. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1578 · Cited by 50 · see citing works
Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus
Mathian, A., Jouenne, R., Chader, D., Aubart, F. C., Haroche, J., Fadlallah, J., Claër, L., Musset, L., Gorochov, G., Amoura, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143689 · Cited by 50 · see citing works
Systemic lupus erythematosus diagnosis and management
Thong, B., & Olsen, N. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kew401 · Cited by 120 · see citing works
Naito, T., Yamada, T., Mino, Y., & Kawakami, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.024 · Cited by 41 · see citing works
Shaharir, S. S., Gafor, A. H. A., Said, M. S. M., & Kong, N. C. T. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12474 · Cited by 39 · see citing works
Pozo, Ó. J., Marcos, J., Matabosch, X., Ventura, R., & Segura, J. (2012) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6129 · Cited by 35 · see citing works
Ruiz‐Irastorza, G., Garcia, M., Espinosa, G., Caminal‐Montero, L., Mitjavila, F., González-León, R., SOPEÑA, B., Canora, J., Villalba, M. V., Rodríguez‐Carballeira, M., et al. (2016) · Lupus Science & Medicine · doi:10.1136/lupus-2016-000153 · Cited by 34 · see citing works
Möhlmann, J. E., Ezzafzafi, S., Lindemans, C. A., Jansen, M. H. A., Nierkens, S., Huitema, A. D. R., & van Luin, M. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01419-7 · Cited by 33 · see citing works
Gabet, Y., Noh, T., Lee, C., & Frenkel, B. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22412 · Cited by 30 · see citing works
Myelitis in systemic lupus erythematosus
Li, X., Xiao, H., & Pai, P. M. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.003 · Cited by 26 · see citing works
The role of corticosteroids in the treatment of Kawasaki disease
Chang, L., & Kuo, H. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1713752 · Cited by 27 · see citing works
Téllez-Arévalo, A. M., Quaye, A., Rojas-Rodríguez, L. C., Poole, B. D., Baracaldo-Santamaría, D., & Freitas, C. M. T. (2022) · Medicina · doi:10.3390/medicina59010056 · Cited by 24 · see citing works
A review of systemic lupus erythematosus and current treatment options
Bailey, T., Rowley, K., & Bernknopf, A. C. (2011) · Cited by 21 · see citing works
Zhang, B., Shi, Y., & Lei, T. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.667 · Cited by 20 · see citing works
Santos, L. F. D. R. F., Costa, N. T., Maes, M. H. J., Simão, A. N. C., & Dichi, I. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00674-6 · Cited by 18 · see citing works
Sugiyama, T., Suzuki, S., Yoshida, T., Suyama, K., Tanaka, T., Sueishi, M., & Tatsuno, I. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.06.004 · Cited by 16 · see citing works
Systemic lupus erythematosus: A genetic review for advanced practice nurses
Robinson, M., Cook, S. S., & Currie, L. M. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00675.x · Cited by 15 · see citing works
Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus.
Ruiz‐Irastorza, G., García, M., Espinosa, G., Cabezas‐Rodríguez, I., Mitjavila, F., González-León, R., SOPEÑA, B., Perales, I., Pinilla, B., Rodríguez‐Carballeira, M., et al. (2016) · PubMed · Cited by 14 · see citing works
Lee, S.-P., Wu, C., Hsieh, L.-C., Cheung, W., & Chou, M. (2014) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2014.02.005 · Cited by 14 · see citing works
Wang, K.-C., Liu, P.-H., Yu, K., Weng, Y.-M., Ng, C., Chiu, T., & Chen, S.-Y. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.03.008 · Cited by 12 · see citing works
Sugiyama, T., Tatsuno, I., Suzuki, S., Yoshida, T., Tanaka, T., Sueishi, M., & Saitō, Y. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-318 · Cited by 11 · see citing works
Wu, W.-H., Liu, J., & Chang, H. (2010) · Expert Systems with Applications · doi:10.1016/j.eswa.2010.06.058 · Cited by 10 · see citing works
Sochet, A. A., Son, S., Ryan, K. S., Roddy, M. R., Barrie, E., Wilsey, M. J., McKinley, S. D., & Nakagawa, T. A. (2019) · Journal of Asthma · doi:10.1080/02770903.2019.1614617 · Cited by 10 · see citing works
Wang, X., Feng, D., Ke, Y., Gu, L., Lv, C., Zhang, M., Wang, Q., & Wang, Y. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s359698 · Cited by 8 · see citing works
Sari, M. K., Satria, C. D., & Arguni, E. (2021) · Global Pediatric Health · doi:10.1177/2333794x211005609 · Cited by 8 · see citing works
Progress and unmet needs in understanding fundamental mechanisms of autoimmunity
Reynolds, J. A., & Putterman, C. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.102999 · Cited by 7 · see citing works
Flower, C., Hennis, A. J. M., & Liang, M. H. (2011) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-011-9080-0 · Cited by 7 · see citing works
Systemic Glucocorticoid Therapy in SLE
Kirou, K. A., & Boumpas, D. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1893-5.00048-0 · Cited by 7 · see citing works
Stress Ulcer Prophylaxis for Critical Asthma
Roberts, A. R., Roddy, M. R., Wilsey, M. J., McKinley, S. D., Teppa, B., & Sochet, A. A. (2022) · PEDIATRICS · doi:10.1542/peds.2021-054527 · Cited by 7 · see citing works
Aslani, N., Raeeskarami, S. R., Aghaei‐Moghadam, E., Tahghighi, F., Assari, R., Sadeghi, P., & Ziaee, V. (2022) · Cureus · doi:10.7759/cureus.26252 · Cited by 7 · see citing works
Bankole, A. A., Kazmi, T. R., & Strazanac, A. R. (2021) · Cureus · doi:10.7759/cureus.20129 · Cited by 6 · see citing works
CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy
Sato, Y., Motoyama, S., Maruyama, K., Yoshino, K., Sasaki, T., Wakita, A., & Ogawa, J. (2012) · Esophagus · doi:10.1007/s10388-012-0316-x · Cited by 6 · see citing works
Treat-to-target in lupus: what does the future hold?
Fanouriakis, A., & Bertsias, G. K. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.15.43 · Cited by 4 · see citing works
Permana, D. Y., Barliana, M., & Hamijoyo, L. (2019) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_212_19 · Cited by 4 · see citing works
Kaneko, M., Hakuno, F., Kamei, H., Yamanaka, D., Chida, K., Minami, S., Coe, I. R., & Takahashi, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.132 · Cited by 4 · see citing works
Corticosteroid and Nonsteroidal Anti-Inflammatory Drug use in Systemic Lupus Erythematosus
Dvorkina, O., & Ginzler, E. M. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10056-7 · Cited by 4 · see citing works
Treatment of Systemic Lupus Erythematosus
Bertsias, G. K., Fanouriakis, A., & Boumpas, D. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00081-5 · Cited by 4 · see citing works
Goodfield, M. J. D., Dutz, J. P., & McCourt, C. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0052 · Cited by 4 · see citing works
Treatment of Systemic Lupus Erythematosus
Bertsias, G. K., Fanouriakis, A., & Boumpas, D. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00081-4 · Cited by 3 · see citing works
Systemic Lupus Erythematosus: A Therapeutic Update
Heyneman, C. A. (2008) · Journal of Pharmacy Practice · doi:10.1177/0897190008322246 · Cited by 3 · see citing works
Glucocorticoid-induced osteoporosis in systemic lupus erythematosus
Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018) · Rheumatology Practice and Research · doi:10.1177/2059902118802510 · Cited by 3 · see citing works
Algorithm for the treatment of systemic lupus erythematosus. Current state of the problem
Klyukvina, N. G. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-8-99-105 · Cited by 1 · see citing works
Effect of ACEA 1021 on Neurotoxicity Induced by Dexamethasone — Initial Behavioral Study
Krasuska-Grzegorczyk, B., Komsta, Ł., & Danilczuk, Z. (2024) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/185546 · Cited by 1 · see citing works
Zúñiga, M. A. V. (2011) · Revista Clínica Escuela de Medicina UCR-HSJD · doi:10.15517/rc_ucr-hsjd.v2i4.6524 · Cited by 1 · see citing works
Wuryana, D., Suryana, B. P. P., & Yulistiani, Y. (2016) · Folia Medica Indonesiana · doi:10.20473/fmi.v51i3.2824 · Cited by 1 · see citing works
Exploiting the Bioenergetics of Disease-Causing Lymphocytes for Selective Immunomodulation.
Wahl, D. R. (2012) · Deep Blue (University of Michigan)
Uso de pegfilgrastim en neutropenia secundaria a lupus eritematoso sistémico; informe de un caso
Solís-Poblano, J. C., & de Armas, M. D. L. L. C. (2010) · Gaceta Mexicana de Oncología
Glukokortikoidi v nefrologiji II: indikacije in odmerjanje
Pajek, J. (2015) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1237
Systemic Lupus Erythematosus in Hospital Patients
Chang, D., & Kerr, L. D. (2014) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2014.06.005
Ocena przebiegu oraz skuteczności stosowanego leczenia toczniowego zapalenia nerek u dzieci
Sołtysiak, J., Silska‐Dittmar, M., Siwińska, A., Ostalska‐Nowicka, D., & Zachwieja, J. (2010) · Pediatria Polska · doi:10.1016/s0031-3939(10)70004-4
Onset of systemic lupus erythematous complicated by severe multiorgan involvement
Forcellini, S., Annaloro, M., Bortot, A., Russo, G., & Battaglia, Y. (2013) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2013.11202
The Treatment of Lupus: General Principles
Massarotti, E. M., & Schur, P. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1189-5_5
Mashaly, H. M., Helal, H. G., & Shaker, O. G. (2011) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000397888.56807.aa
Rapidly resolved IgG4-related retroperitoneal fibrosis after steroid pulse therapy
Jeung, S., Kim, H., Seo, Y., Yoon, H., Lee, N. K., Park, S., Seo, B., Park, S., & Park, S.-K. (2016) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2016.33.1.40
Janssen, E., Shulman, A. I., & Sundel, R. P. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0271-2.00014-6
Transverse myelitis as a rare presentation of antiphospholipid-antibody-associated disorders
Berek, K., Fava, E., Zinganell, A., Hegen, H., Auer, M., Wurth, S., Rhomberg, P., Deisenhammer, F., & Pauli, F. D. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102405
Lupus eritematoso sistemico all'esordio complicato da un severo coinvolgimento multiorgano
Forcellini, S., Annaloro, M., Bortot, A., Russo, G., & Battaglia, Y. (2013) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2013.1019
Aslani, N., Raeeskarami, S.-R., Aghaei‐Moghadam, E., Tahghighi, F., Assari, R., Sadeghi, P., & Ziaee, V. (2021) · Research Square · doi:10.21203/rs.3.rs-460428/v1
Carlomagno, A., Silveira, G., Danza, Ã., Pizzarossa, A. C., Yandián, M., Yandián, F., & Rebella, M. (2021) · Revista Médica del Uruguay · doi:10.29193/rmu.37.4.6
Bertsias, G. K., Sidiropoulos, P. I., & Boumpas, D. T. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00132-9
Catatonia secundária ao lúpus eritematoso sistêmico: Revisão sistemática
de Figueiredo, J. C. Q., Aquino, R. D. S., & de Figueiredo, E. C. Q. (2022) · Research Society and Development · doi:10.33448/rsd-v11i11.33412
An Osteopathic Approach to the Management of Systemic Lupus Erythematosus
Hoelscher, A. M., Sonnenberg, G., Smith, M., Fritz, D., Belanger, A., & Toffol, R. (2023) · Osteopathic Family Physician · doi:10.33181/13098
The phenotype of systemic lupus erythematosus as a factor in rational therapy choosing
Babaeva, A. R., Калинина, Е. В., & Goloskova, V. P. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-10-7-12
Bourke, L. (2014) · UCL Discovery (University College London)
- Authors
- Parker, B., & Bruce, I.
- Affiliations
- The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children's NHS Trust, Manchester Royal Infirmary
- The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children's NHS Trust, Manchester Royal Infirmary, ARC Epidemiology Unit, The University of Manchester, Manchester, UK,
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2007-06
- Volume
- 16
- Issue
- 6
- Pages
- 387-393
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2028833675
- Cited by
- 80
- References
- 42
- Citations by year
- 2024: 4 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 8 · 2015: 4 · 2014: 6 · 2013: 5 · 2012: 6
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- systemic lupus erythematosus, intravenous methylprednisolone, high-dose corticosteroids, acute flare, maintenance therapy, renal survival, cyclophosphamide, oral prednisolone, corticosteroid therapy
- MeSH terms
- Adrenal Cortex Hormones, Dose-Response Relationship, Drug, Glucocorticoids, Humans, Injections, Intravenous, Lupus Erythematosus, Systemic, Methylprednisolone, Rheumatology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
